Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2]. Core Insights - The report highlights a marginal easing of tariff policies, suggesting a potential recovery in consumption and export sectors within the industry [3][12]. - The pharmaceutical and biotechnology sector has shown a weekly return of 1.01%, ranking 26th among 31 primary sub-industry indices, with medical devices leading at 1.67% [3][27]. - Recent government policies, such as the establishment of geriatric medicine departments in hospitals and new regulations for drug wholesale management in the Beijing-Tianjin-Hebei region, are expected to positively impact the industry [3][47]. Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector's performance over the past month was a return of 4.77%, ranking 19th among 31 primary sub-industry indices [3][14]. - The sector's current PE (TTM) is 26.29 times, which is below the historical average of 31.15 times, indicating a relatively low valuation [20][21]. 2. Market Performance - The report notes that the recent three-month performance shows a decline of 1.88%, while the six-month performance indicates a drop of 7.71% [15][16]. - The report suggests that the easing of tariff impacts may lead to a valuation recovery in specific sub-sectors such as CXO, raw materials, and medical devices [3][12]. 3. Export Industry Chain - The report recommends focusing on the export industry chain, particularly in the CXO sector, with key companies including WuXi AppTec and others highlighted for potential investment [3][12]. - In the raw materials sector, companies like Junshi Biosciences and others are suggested for attention [3][12]. 4. Consumption Recovery - The report anticipates that monetary policies such as interest rate cuts and reserve requirement ratio reductions will enhance macroeconomic consumption [3][12]. - Specific sectors for investment include ophthalmology and dental care, medical aesthetics, traditional Chinese medicine, and retail pharmacy leaders [3][12]. 5. Industry Dynamics - Recent policy developments include the release of guidelines for geriatric medicine and new regulations for drug wholesale management, which are expected to foster healthy development in the pharmaceutical distribution sector [3][47]. - Notable industry news includes collaborations between major pharmaceutical companies and health platforms, as well as significant investments in local production facilities [47].